Strength Seen in Revvity (RVTY): Can Its 9.1% Jump Turn into More Strength?

Revvity (RVTY) shares ended the last trading session 9.1% higher at $140.19. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 10.6% gain over the past four weeks.

The sharp rise in RVTY shares can be attributed to the company's upbeat commentary on AI-driven demand for its research tools, improving order backlog and a wave of favorable analyst actions following its presentation at the 2026 Global Healthcare Conference. Investor sentiment was further supported by Revvity's planned acquisition of Human Cell Design, which strengthens its capabilities in GLP-1 obesity and diabetes research, reinforcing confidence in the company's long-term growth prospects.

This maker of scientific instruments is expected to post quarterly earnings of $1.28 per share in its upcoming report, which represents a year-over-year change of +8.5%. Revenues are expected to be $702.56 million, up 0.5% from the year-ago quarter.

Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.

For Revvity, the consensus EPS estimate for the quarter has been revised marginally lower over the last 30 days to the current level. And a negative trend in earnings estimate revisions doesn't usually translate into price appreciation. So, make sure to keep an eye on RVTY going forward to see if this recent jump can turn into more strength down the road.

The stock currently carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>

Revvity is a member of the Zacks Medical Services industry. One other stock in the same industry, Caris Life Sciences,?Inc. (CAI), finished the last trading session 9.4% higher at $28.5. CAI has returned 20.4% over the past month.

For Caris Life Sciences,?Inc., the consensus EPS estimate for the upcoming report has remained unchanged over the past month at $0.03. This represents a change of -62.5% from what the company reported a year ago. Caris Life Sciences,?Inc. currently has a Zacks Rank of #3 (Hold).

Zacks' Research Chief Names "Stock Most Likely to Double"

Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.

This innovative software-as-a-service firm upped its user base +22% year over year. That rate is increasing and margins are expanding as AI efficiencies take effect. Of course, all our elite picks aren't winners, but this one could far surpass earlier Zacks' Stocks Set to Double like D-Wave Quantum, which shot up +680.1%.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research